


Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-Dec-2022  
Document Type: USP Monographs  
DocId: GUID-295AFF3A-283C-44FF-BF46-3582678AC343\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M3453\\_02\\_01](https://doi.org/10.31003/USPNF_M3453_02_01)  
DOI Ref: 2370t

© 2025 USPC  
Do not distribute

**Add the following:**

## ^Etravirine



$C_{20}H_{15}BrN_6O$  435.29

Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-; 4-((6-Amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile CAS RN®: 269055-15-4; UNII: 0C50HW4F01.

### DEFINITION

Etravirine contains NLT 98.0% and NMT 102.0% of etravirine ( $C_{20}H_{15}BrN_6O$ ), calculated on the anhydrous and solvent-free basis.

### IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K or 197A
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

Protect solutions containing etravirine from light.

**Buffer:** 10 mM [ammonium formate](#) in [water](#)

**Diluent:** [Acetonitrile](#) and **Buffer** (10:9, v/v)

**Solution A:** 50 mM [formic acid](#) in **Buffer**

**Solution B:** [Acetonitrile](#)

**Solution C:** [Methanol](#)

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution A (%)	Solution B (%)	Solution C (%)
0	60	30	10
35	0	0	100
37	60	30	10
45	60	30	10

**Standard stock solution:** 2.0 mg/mL of [USP Etravirine RS](#) in [1-methyl-2-pyrrolidone](#)

**Standard solution:** 0.10 mg/mL of [USP Etravirine RS](#) from the *Standard stock solution* in *Diluent*

**Sample stock solution:** 2.0 mg/mL of Etravirine in [1-methyl-2-pyrrolidone](#)

**Sample solution:** 0.10 mg/mL of Etravirine from the *Sample stock solution* in *Diluent*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 310 nm

**Column:** 3.0-mm × 15-cm; 5-μm packing [L1](#)

**Column temperature:** 35°

**Flow rate:** 0.6 mL/min

**Injection volume:** 10 μL

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 1.5

**Relative standard deviation:** NMT 0.73%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of etravirine ( $C_{20}H_{15}BrN_6O$ ) in the portion of Etravirine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of etravirine from the *Sample solution*

$r_S$  = peak response of etravirine from the *Standard solution*

$C_S$  = concentration of [USP Etravirine RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Etravirine in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0%, on the anhydrous and solvent-free basis

#### IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

#### ORGANIC IMPURITIES

Protect solutions containing etravirine from light.

**Buffer, Diluent, Solution A, Solution B, Solution C, Mobile phase, Standard stock solution, Standard solution, Sample stock solution, Sample solution, and Chromatographic system:** Proceed as directed in the Assay.

**System suitability solution:** 0.10 mg/mL of [USP Etravirine System Suitability Mixture RS](#) prepared as follows. Transfer a suitable amount of [USP Etravirine System Suitability Mixture RS](#) to a suitable volumetric flask and dissolve in 10% of the total volume of [1-methyl-2-pyrrolidone](#). Dilute with *Diluent* to volume.

**Sensitivity solution:** 0.05 μg/mL of [USP Etravirine RS](#) from the *Standard solution* in *Diluent*

#### System suitability

**Samples:** *Standard solution*, *System suitability solution*, and *Sensitivity solution*

[**NOTE**—The relative retention times for etravirine amino analog and desbromoetravirine in relation to etravirine are 0.66 and 0.73, respectively.]

#### Suitability requirements

**Resolution:** NLT 4.3 between etravirine amino analog and desbromoetravirine, *System suitability solution*

**Relative standard deviation:** NMT 0.73%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of any individual impurity in the portion of Etravirine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

$r_U$  = peak response of any individual impurity from the *Sample solution*

$r_S$  = peak response of etravirine from the *Standard solution*

$C_S$  = concentration of [USP Etravirine RS](#) in the *Standard solution* (mg/mL) $C_U$  = concentration of Etravirine in the *Sample solution* (mg/mL) $F$  = relative response factor (see [Table 2](#))**Acceptance criteria:** See [Table 2](#). The reporting threshold is 0.05%.**Table 2**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Etravirine amino analog <sup>a,b</sup>	0.66	1.3	—
Desbromoetravirine <sup>c,b</sup>	0.73	1.0	—
Etravirine	1.0	1.0	—
Etravirine butanamide analog <sup>d</sup>	1.08	0.77	0.30
Etravirine dimer <sup>e</sup>	1.41	0.86	0.50
Any individual unspecified impurity	—	1.0	0.10
Total impurities	—	—	1.0

<sup>a</sup> 4-[(4-Amino-5-bromo-6-chloropyrimidin-2-yl)amino]benzonitrile.<sup>b</sup> For peak identification purpose. If present, these impurities are covered under acceptance criteria for any individual unspecified impurity.<sup>c</sup> 4-[(6-Amino-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy]-3,5-dimethylbenzonitrile.<sup>d</sup> 4-[(5-Bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]pyrimidin-4-yl](methyl)amino]butanamide.<sup>e</sup> 4,4'-{[5-Bromo-2-[(4-cyanophenyl)amino]pyrimidine-4,6-diyl]bis(oxy)}bis(3,5-dimethylbenzonitrile).**SPECIFIC TESTS**

- [WATER DETERMINATION \(921\), Method I, Method Ia](#): NMT 0.5%

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, and store at room temperature.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Etravirine RS](#)[USP Etravirine System Suitability Mixture RS](#) ▲ (USP 1-Dec-2022)Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ETRAVIRINE	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 47(3)

**Current DocID:** [GUID-295AFF3A-283C-44FF-BF46-3582678AC343\\_2\\_en-US](#)**DOI:** [https://doi.org/10.31003/USPNF\\_M3453\\_02\\_01](https://doi.org/10.31003/USPNF_M3453_02_01)

OFFICIAL